MX2017013881A - Composiciones y metodos para la vigilancia activa del cancer de prostata. - Google Patents

Composiciones y metodos para la vigilancia activa del cancer de prostata.

Info

Publication number
MX2017013881A
MX2017013881A MX2017013881A MX2017013881A MX2017013881A MX 2017013881 A MX2017013881 A MX 2017013881A MX 2017013881 A MX2017013881 A MX 2017013881A MX 2017013881 A MX2017013881 A MX 2017013881A MX 2017013881 A MX2017013881 A MX 2017013881A
Authority
MX
Mexico
Prior art keywords
prostate cancer
methods
compositions
active surveillance
surveillance
Prior art date
Application number
MX2017013881A
Other languages
English (en)
Inventor
j vickers Andrew
T Scardino Peter
Lilja Hans
Dong Yan
SJOBERG Daniel
Original Assignee
Opko Diagnostics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opko Diagnostics Llc filed Critical Opko Diagnostics Llc
Publication of MX2017013881A publication Critical patent/MX2017013881A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
    • G06N7/00—Computing arrangements based on specific mathematical models
    • G06N7/01—Probabilistic graphical models, e.g. probabilistic networks
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96455—Kallikrein (3.4.21.34; 3.4.21.35)

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Medical Informatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Theoretical Computer Science (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Physics & Mathematics (AREA)
  • Data Mining & Analysis (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • Biophysics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Databases & Information Systems (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Evolutionary Computation (AREA)
  • Probability & Statistics with Applications (AREA)
  • Mathematical Physics (AREA)

Abstract

Aspectos de la divulgación se refieren a métodos y sistemas mejorados para la vigilancia activa de un sujeto que tiene cáncer de próstata no agresivo.
MX2017013881A 2015-04-29 2016-04-29 Composiciones y metodos para la vigilancia activa del cancer de prostata. MX2017013881A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562154616P 2015-04-29 2015-04-29
PCT/US2016/029959 WO2016176529A1 (en) 2015-04-29 2016-04-29 Compositions and methods for active surveillance of prostate cancer

Publications (1)

Publication Number Publication Date
MX2017013881A true MX2017013881A (es) 2018-03-12

Family

ID=57198800

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017013881A MX2017013881A (es) 2015-04-29 2016-04-29 Composiciones y metodos para la vigilancia activa del cancer de prostata.

Country Status (21)

Country Link
US (2) US20160320394A1 (es)
EP (2) EP3287786A3 (es)
JP (1) JP6873916B2 (es)
KR (1) KR102527446B1 (es)
CN (1) CN107530412A (es)
AU (1) AU2016254127B2 (es)
BR (1) BR112017022391A2 (es)
CA (1) CA2982262A1 (es)
CL (1) CL2017002701A1 (es)
CO (1) CO2017010808A2 (es)
DE (1) DE202016008673U1 (es)
EA (1) EA039028B1 (es)
HK (2) HK1247559A1 (es)
IL (1) IL254833B (es)
MX (1) MX2017013881A (es)
MY (1) MY197117A (es)
PE (1) PE20180930A1 (es)
SG (1) SG11201708289TA (es)
TW (1) TWI766836B (es)
UA (1) UA125745C2 (es)
WO (1) WO2016176529A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE202010018623U1 (de) 2009-02-02 2018-12-07 Opko Diagnostics, Llc Strukturen zur Steuerung der Lichtwechselwirkung mit mikrofluidischen Vorrichtungen
EA036387B1 (ru) 2012-03-05 2020-11-03 Ой Арктик Партнерс Аб Способы и аппараты для прогнозирования риска рака предстательной железы и объема предстательной железы
US11761962B2 (en) 2014-03-28 2023-09-19 Opko Diagnostics, Llc Compositions and methods related to diagnosis of prostate cancer
MX2017012320A (es) 2015-03-27 2018-01-18 Opko Diagnostics Llc Estandares de antigeno prostatico y sus usos.
US10852310B2 (en) 2015-12-11 2020-12-01 Opko Diagnostics, Llc Fluidic systems involving incubation of samples and/or reagents
HUE055156T2 (hu) 2015-12-29 2021-11-29 Opko Diagnostics Llc Folyadékgyûjtési eszköz és kapcsolódó módszerek
EP3794354A4 (en) * 2018-05-16 2022-01-12 Opko Diagnostics, LLC METHODS OF DETECTING PROSTATE CANCER ASSOCIATED WITH NEGATIVE RESULTS

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7211397B2 (en) * 1999-04-30 2007-05-01 Beckman Coulter, Inc. Method of analyzing non-complexed forms of prostate specific antigen in a sample to improve prostate cancer detection
WO2011027310A1 (en) * 2009-09-03 2011-03-10 Koninklijke Philips Electronics N.V. Novel tumor markers
EA023941B1 (ru) 2010-04-16 2016-07-29 Опкоу Дайагностикс, Ллк. Анализатор микрофлюидного образца и способ выполнения анализа микрофлюидного образца
EA036387B1 (ru) * 2012-03-05 2020-11-03 Ой Арктик Партнерс Аб Способы и аппараты для прогнозирования риска рака предстательной железы и объема предстательной железы
US20150094221A1 (en) * 2012-05-16 2015-04-02 Phadia Ab Method for Indicating the Presence or Non-Presence of Prostate Cancer
AU2013349721B2 (en) * 2012-11-20 2019-03-28 Phadia Ab Prognostic method for individuals with prostate cancer
CA3092807C (en) * 2012-11-20 2024-02-27 Phadia Ab Method for indicating a presence or non-presence of aggressive prostate cancer

Also Published As

Publication number Publication date
CA2982262A1 (en) 2016-11-03
UA125745C2 (uk) 2022-06-01
EA201792372A1 (ru) 2018-03-30
EP3287786A2 (en) 2018-02-28
CO2017010808A2 (es) 2018-04-19
CN107530412A (zh) 2018-01-02
IL254833B (en) 2021-12-01
JP2018518661A (ja) 2018-07-12
MY197117A (en) 2023-05-26
DE202016008673U1 (de) 2019-01-22
AU2016254127A1 (en) 2017-10-26
TW201705028A (zh) 2017-02-01
EP3287786A3 (en) 2018-03-21
JP6873916B2 (ja) 2021-05-19
HK1247824A1 (zh) 2018-10-05
EA039028B1 (ru) 2021-11-24
WO2016176529A1 (en) 2016-11-03
IL254833A0 (en) 2017-12-31
HK1247559A1 (zh) 2018-09-28
SG11201708289TA (en) 2017-11-29
KR102527446B1 (ko) 2023-05-02
US20220399121A1 (en) 2022-12-15
PE20180930A1 (es) 2018-06-08
BR112017022391A2 (pt) 2018-07-10
TWI766836B (zh) 2022-06-11
KR20180018514A (ko) 2018-02-21
US20160320394A1 (en) 2016-11-03
EP3247387A4 (en) 2018-09-12
AU2016254127B2 (en) 2022-05-26
EP3247387A1 (en) 2017-11-29
CL2017002701A1 (es) 2018-07-06

Similar Documents

Publication Publication Date Title
PH12018500950A1 (en) Subcutaneous formulations of anti-cd38 antibodies and their uses
PH12018500711A1 (en) Anti-pd1 antibodies and methods of use
MX2020009461A (es) Anticuerpos anti-proteína que contiene dominio de inmunologlubina rfig elacionado con el receptor de poliovirus (pvrig) y métodos de uso.
PH12016501143A1 (en) Anti-cd33 antibodies and immunoconjugates
MY197117A (en) Compositions and methods for active surveillance of prostate cancer
PH12015501954A1 (en) Anti-b7-h4 antibodies and immunoconjugates
MA40579A (fr) Anticorps anti-cll-1 et immunoconjugués
MY176285A (en) Anti-fcrh5 antibodies
MX370807B (es) Anticuerpos que se unen a axl.
AU2015287674B2 (en) Topical antiviral compositions and methods of using the same
MX2016004570A (es) Uso de inhibidores del bromodominio de cbp/ep300 para la inmunoterapia del cáncer.
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
GB2569488A (en) PD-1 specific aptamers
PH12016501838A1 (en) Compounds and their methods of use
MX2015013021A (es) 5-bromo-indirrubinas.
MY187959A (en) Reactor
EP4233977A3 (en) Access visualization systems
NZ721832A (en) Solid forms of tenofovir
MX2016004573A (es) Inhibidores de nsp4 y metodos de uso.
MX2015010789A (es) Anticuerpos anti-pcsm.
IN2013MU03768A (es)
IN2014CH00872A (es)
UA104671U (uk) Застосування яктону як нейропротектора